Drugs /

fianlimab

Back to Drugs List

Overview

NCI Definition [1]:
A monoclonal antibody directed against the inhibitory receptor lymphocyte activation gene-3 protein (LAG-3; LAG3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, fianlimab binds to LAG-3 expressed by tumor infiltrating lymphocytes (TILs) and blocks LAG-3 binding to tumor cells expressing major histocompatibility complex (MHC) class II molecules. This may activate antigen-specific T-lymphocytes and enhance cytotoxic T-lymphocyte (CTL)-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells; its expression on TILs is associated with tumor-mediated immune suppression and the negative regulation of both cellular proliferation and T-cell activation.

Clinical Trials

View Clinical Trials for fianlimab

Fianlimab has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating fianlimab, 1 is phase 1 (1 open) and 1 is phase 2 (1 open).

Invasive breast carcinoma, lymphoma, and malignant solid tumor are the most common diseases being investigated in fianlimab clinical trials [2].

Drug Details

Synonyms [2]:
who 11182, anti-lag-3 moab regn3767, regn 3767, regn3767
Drug Target(s) [2]:
LAG3
NCIT ID [1]:
C132339

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.